A Comparative Study of Postadrenalectomy Hyperuricemia and Renal Impairment in Patients with Unilateral Primary Aldosteronism: Does Histopathology Subtype Matter?

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2024 Oct 13

PMID 39396977

Authors

Chu-Wen Fang

Hui-Lung Hsieh

Shuo-Meng Wang

Kuo-How Huang

Kang-Yung Peng

Yen-Hung Lin

Vin-Cent Wu

Jeff S Chueh

Affiliations

Soon will be listed here.

Abstract

Background: Primary aldosteronism (PA), which is present in 5-18% of hypertensive patients, is a leading cause of secondary hypertension. Adrenalectomy is often recommended for patients with unilateral primary aldosteronism (uPA), yielding good long-term outcomes. PA patients without hyperuricemia and chronic renal failure before adrenalectomy were enrolled in this cohort study. Serum uric acid (SUA) and renal filtration were measured one year post-adrenalectomy. Their relationships with pathologic features, histopathological subtype (classical or nonclassical (HISTALDO consensus)), and vessel stiffness were explored. The aim of this cohort study is to evaluate the correlation between post-adrenalectomy serum uric acid (SUA) levels and estimated glomerular filtration rate (eGFR) with the pathologic features delineated by the HISTALDO consensus. Additionally, the study seeks to assess the impact of these biochemical markers on peripheral vessel stiffness and brachial-ankle pulse wave velocity (baPWV) at a one-year follow-up visit.

Methods: This prospective cohort study included patients (N = 100) diagnosed with uPA who underwent adrenalectomy from Jan 1, 2007 to Dec 31, 2022.

Results: At follow-up, elevated SUA, hyperuricemia, and a > 25% eGFR decrease were significantly more common in the classical than the nonclassical group. The incidence of postoperative hyperuricemia, herein referred to as post-adrenalectomy hyperuricemia (PAHU), was 29% (29/100) overall, 34.8% (23/66) in the classical group and 17.6% (6/34) in the nonclassical group. The incidence of eGFR reduction > 25% was 33% (33/100), 43.9% (29/66), and 11.8% (4/34), respectively. baPWV decreased more in the classical group than the nonclassical group.

Conclusion: For PA patients with PAHU and/or renal impairment, we suggest monitoring SUA, pH, urine uric acid, and urine crystals and performing a KUB study and peripheral vascular and renal sonography (on which pure uric acid stones in the KUB are radiolucent) to determine whether drug intervention is required for cases of asymptomatic PAHU, especially patients in male gender, classical histopathology, or renal impairment.

References

Savard S, Amar L, Plouin P, Steichen O . Cardiovascular complications associated with primary aldosteronism: a controlled cross-sectional study. Hypertension. 2013; 62(2):331-6. DOI: 10.1161/HYPERTENSIONAHA.113.01060. View

Otsuka H, Abe M, Kobayashi H . The Effect of Aldosterone on Cardiorenal and Metabolic Systems. Int J Mol Sci. 2023; 24(6). PMC: 10049192. DOI: 10.3390/ijms24065370. View

Krishnan E . Reduced glomerular function and prevalence of gout: NHANES 2009-10. PLoS One. 2012; 7(11):e50046. PMC: 3507834. DOI: 10.1371/journal.pone.0050046. View

Meyer L, Handgriff L, Lim J, Udager A, Kinker I, Ladurner R . Single-Center Prospective Cohort Study on the Histopathology, Genotype, and Postsurgical Outcomes of Patients With Primary Aldosteronism. Hypertension. 2021; 78(3):738-746. DOI: 10.1161/HYPERTENSIONAHA.121.17348. View

Kramers B, Kramers C, Lenders J, Deinum J . Effects of Treating Primary Aldosteronism on Renal Function. J Clin Hypertens (Greenwich). 2016; 19(3):290-295. PMC: 8031144. DOI: 10.1111/jch.12914. View

Williams T, Gomez-Sanchez C, Rainey W, Giordano T, Lam A, Marker A . International Histopathology Consensus for Unilateral Primary Aldosteronism. J Clin Endocrinol Metab. 2020; 106(1):42-54. PMC: 7765663. DOI: 10.1210/clinem/dgaa484. View

Toyama T, Furuichi K, Shimizu M, Hara A, Iwata Y, Sakai N . Relationship between Serum Uric Acid Levels and Chronic Kidney Disease in a Japanese Cohort with Normal or Mildly Reduced Kidney Function. PLoS One. 2015; 10(9):e0137449. PMC: 4565699. DOI: 10.1371/journal.pone.0137449. View

Ogata H, Yamazaki Y, Tezuka Y, Gao X, Omata K, Ono Y . Renal Injuries in Primary Aldosteronism: Quantitative Histopathological Analysis of 19 Patients With Primary Adosteronism. Hypertension. 2021; 78(2):411-421. PMC: 8597934. DOI: 10.1161/HYPERTENSIONAHA.121.17436. View

Waheed Y, Yang F, Sun D . Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease. Korean J Intern Med. 2020; 36(6):1281-1293. PMC: 8588983. DOI: 10.3904/kjim.2020.340. View

10.

Correa-Costa M, Braga T, Semedo P, Hayashida C, Grassmann Bechara L, Elias R . Pivotal role of Toll-like receptors 2 and 4, its adaptor molecule MyD88, and inflammasome complex in experimental tubule-interstitial nephritis. PLoS One. 2011; 6(12):e29004. PMC: 3237574. DOI: 10.1371/journal.pone.0029004. View

11.

Wu V, Chan C, Chueh J, Chen Y, Lin Y, Chang C . Markers of Kidney Tubular Function Deteriorate While Those of Kidney Tubule Health Improve in Primary Aldosteronism After Targeted Treatments. J Am Heart Assoc. 2023; 12(4):e028146. PMC: 10111488. DOI: 10.1161/JAHA.122.028146. View

12.

Sheu J, Wang S, Wu V, Huang K, Tseng C, Lee Y . Estimated glomerular filtration rate-dip after medical target therapy associated with increased mortality and cardiovascular events in patients with primary aldosteronism. J Hypertens. 2023; 41(9):1401-1410. DOI: 10.1097/HJH.0000000000003479. View

13.

Schepers M, van Ballegooijen E, Bangma C, Verkoelen C . Crystals cause acute necrotic cell death in renal proximal tubule cells, but not in collecting tubule cells. Kidney Int. 2005; 68(4):1543-53. DOI: 10.1111/j.1523-1755.2005.00566.x. View

14.

Shiizaki K, Tsubouchi A, Miura Y, Seo K, Kuchimaru T, Hayashi H . Calcium phosphate microcrystals in the renal tubular fluid accelerate chronic kidney disease progression. J Clin Invest. 2021; 131(16). PMC: 8363285. DOI: 10.1172/JCI145693. View

15.

Kohagura K, Kochi M, Miyagi T, Kinjyo T, Maehara Y, Nagahama K . An association between uric acid levels and renal arteriolopathy in chronic kidney disease: a biopsy-based study. Hypertens Res. 2012; 36(1):43-9. DOI: 10.1038/hr.2012.135. View

16.

Klauser A, Halpern E, Strobl S, Gruber J, Feuchtner G, Bellmann-Weiler R . Dual-Energy Computed Tomography Detection of Cardiovascular Monosodium Urate Deposits in Patients With Gout. JAMA Cardiol. 2019; 4(10):1019-1028. PMC: 6739730. DOI: 10.1001/jamacardio.2019.3201. View

17.

Juraschek S, Kovell L, Miller 3rd E, Gelber A . Association of kidney disease with prevalent gout in the United States in 1988-1994 and 2007-2010. Semin Arthritis Rheum. 2013; 42(6):551-61. PMC: 3754853. DOI: 10.1016/j.semarthrit.2012.09.009. View

18.

Namba M, Kikuchi K, Komura H, Suzuki S, Satoh N, Ohtomo T . [Study on uric acid metabolism in patients with primary aldosteronism]. Nihon Naibunpi Gakkai Zasshi. 1992; 68(1):51-61. DOI: 10.1507/endocrine1927.68.1_51. View

19.

Bignardi P, Ido D, Garcia F, Braga L, Delfino V . Does uric acid-lowering treatment slow the progression of chronic kidney disease? A meta-analysis of randomized controlled trials. Nefrologia (Engl Ed). 2022; 43(2):167-181. DOI: 10.1016/j.nefroe.2022.04.005. View

20.

Sautin Y, Johnson R . Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids. 2008; 27(6):608-19. PMC: 2895915. DOI: 10.1080/15257770802138558. View